Neurovation Labs, Inc. is a preclinical stage biotechnology company developing precision medicines and companion imaging diagnostics for CNS disorders using their proprietary region-specific drug discovery platform. The company is currently optimizing its lead asset, an amygdala-specific glutamate receptor inhibitor for PTSD, designed to treat the disease at its source. Their differentiated approach will replace the existing ineffective options and unlock previously inaccessible receptor targets for novel treatments.